Browse Health
Oncology Specialist (cancer)
40 years of experience
Video profile
Accepting new patients

Education ?

Medical School Score
University of Puerto Rico (1970)
  • Currently 1 of 4 apples

Awards & Distinctions ?

On-Time Doctor Award (2014)
Castle Connolly Top Doctors: Texas™ (2009)
American Board of Internal Medicine

Affiliations ?

Dr. Negron is affiliated with 11 hospitals.

Hospital Affilations



  • Texas Health Harris Methodist Hospital Azle
    108 Denver Trl, Azle, TX 76020
    • Currently 3 of 4 crosses
    Top 50%
  • Baylor Medical Center at Southwest Fort Worth
    1400 8th Ave, Fort Worth, TX 76104
    • Currently 3 of 4 crosses
    Top 50%
  • Plaza Medical Center
    900 8th Ave, Fort Worth, TX 76104
    • Currently 1 of 4 crosses
  • Harris Methodits Hospital
  • TX Health Harris Methodist Hospital Fort Worth
  • TX Health Southwest Fw
  • TX Health Fort Worth
  • Harris Continued Care Hospital *
    1301 Pennsylvania Ave, Fort Worth, TX 76104
  • Baylor All Saints Medical Centers *
  • Texas Health Harris Methodist Hospital Southwest Fort Worth
  • Texas Health Harris Methodist Hospital Fort Worth
  • * This information was reported to Vitals by the doctor or doctor's office.

    Publications & Research

    Dr. Negron has contributed to 3 publications.
    Title Comparison of Menopausal Symptoms During the First Year of Adjuvant Therapy with Either Exemestane or Tamoxifen in Early Breast Cancer: Report of a Tamoxifen Exemestane Adjuvant Multicenter Trial Substudy.
    Date November 2007
    Journal Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology

    PURPOSE: Hormonal breast cancer treatment increases menopausal symptoms in women. This study investigated differences between the symptoms associated with either adjuvant tamoxifen or exemestane. PATIENTS AND METHODS: Ten common symptoms were assessed by self-report questionnaire administered to 1,614 consecutive patients at baseline and every 3 months during the first year of a double-blind, randomized trial of postmenopausal women with early hormone receptor-positive breast cancer. Symptoms were categorized as none, mild, moderate, or severe. A hot flash score was calculated at each time point. Symptoms were analyzed by repeated-measures analysis of variance. Each time period was tested repeatedly against the baseline; an overall P value was assigned for each reported symptom. RESULTS: Compliance was excellent, with 7,286 questionnaires analyzed. Baseline symptom prevalence ranged from 2% (vaginal bleeding) to 60% to 70% (bone/muscle aches and low energy). There were no significant differences in vaginal bleeding, mood alteration, or low energy. Patients receiving tamoxifen had significantly more vaginal discharge (P < .0001). Exemestane patients reported more bone/muscle aches (P < .0001), vaginal dryness (P = .0004), and difficulty sleeping (P = .03). In both groups, the hot flash score peaked at 3 months and decreased thereafter. At 12 months, patients receiving tamoxifen had a significantly higher mean hot flash score (P = .03), with daily hot flashes increasing from baseline by 33% compared with a 7% increase from baseline with exemestane. CONCLUSION: At 12 months, exemestane was associated with fewer hot flashes and less vaginal discharge than tamoxifen, but with more vaginal dryness, bone/muscle aches, and difficulty sleeping. Symptoms were common in both groups.

    Title Phase Iii Trial Comparing Doxorubicin Plus Cyclophosphamide with Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer.
    Date December 2006
    Journal Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology

    PURPOSE: The combination of doxorubicin and cyclophosphamide (AC) is a standard adjuvant chemotherapy regimen. Studies of docetaxel and cyclophosphamide (TC) in metastatic breast cancer (MBC) showed promise in MBC. In 1997, we initiated a randomized adjuvant trial of TC compared with standard-dose AC with a primary end point of disease-free survival (DFS). PATIENTS AND METHODS: Patients were eligible if they had stage I to III operable invasive breast cancer with complete surgical excision of the primary tumor. Between June 1997 and December 1999, 1,016 patients were randomly assigned to four cycles of either standard-dose AC (60 and 600 mg/m2, respectively; n = 510) or TC (75 and 600 mg/m2, respectively; n = 506), administered intravenously every 3 weeks as adjuvant chemotherapy. Radiation therapy (as indicated) and tamoxifen, for patients with hormone receptor-positive disease, were administered after completion of chemotherapy. RESULTS: Both treatment groups (TC and AC) were well balanced with respect to major prognostic factors. Patients were observed through 2005 for a median of 5.5 years. At 5 years, DFS rate was significantly superior for TC compared with AC (86% v 80%, respectively; hazard ratio [HR] = 0.67; 95% CI, 0.50 to 0.94; P = .015). Overall survival rates for TC and AC were 90% and 87%, respectively (HR = 0.76; 95% CI, 0.52 to 1.1; P = .13). More myalgia, arthralgia, edema, and febrile neutropenia occurred on the TC arm; more nausea and vomiting occurred on the AC arm as well as one incident of congestive heart failure. CONCLUSION: At 5 years, TC was associated with a superior DFS and a different toxicity profile compared with AC.

    Title The Association of W17 with Familial Renal Cell Carcinoma.
    Date December 1975
    Journal Tissue Antigens

    Similar doctors nearby

    Dr. Robert Ruxer

    Internal Medicine
    32 years experience
    Fort Worth, TX

    Dr. John Nugent

    Medical Oncology
    37 years experience
    Fort Worth, TX

    Dr. Noelle Cloven

    Obstetrics & Gynecology
    17 years experience
    Fort Worth, TX

    Dr. Kenneth Hancock

    Obstetrics & Gynecology
    32 years experience
    Fort Worth, TX

    Dr. Mark Redrow

    Internal Medicine
    26 years experience
    Fort Worth, TX

    Dr. James Bordelon

    Internal Medicine
    42 years experience
    Fort Worth, TX
    Search All Similar Doctors